Peginterferon α-2b plus ribavirin compared with interferon α -2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4

Liver International

Volumn 24, Issue 6, 2004, Pages 568-574

  Alfaleh, F Z ^a   Hadad, Q ^b   Khuroo, M S ^c   Aljumah, A ^d   Algamedi, A ^a   Alashgar, H ^c   Al Ahdal, M N ^c   Mayet, I ^a   Khan, M Q ^c   Kessie, G ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b SECURITY FORCES HOSPITAL   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

Author keywords

Genotype4; Hepatitis C; Pegylated interferon ; Ribavirin

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2B; REBETRON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEMOGLOBINOPATHY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; THYROID DISEASE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; RIBAVIRIN; RISK ASSESSMENT; RNA, VIRAL; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 19944409281     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0976.x     Document Type: Article

References (30)

1. Alter M J, Mast E E. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-55.
2. Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. Abdel-Aziz F, Habib M, Mohamed M K, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32: 111-5.
4. Habib M, Mohamed M K, Abdel-Aziz F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001; 33: 248-53.
5. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83.
6. Al-Faleh F Z, Ramia S, Arif M, et al. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: a community-based study. Ann Trop Med Parasitol 1995; 89: 431-7.
7. Al-Faleh F Z, Ayoola E A, Al-Jeffry M, et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community- based study. Hepatology 1991; 14: 215-8.
8. Al-Faleh F Z, Ayoola E A, Al-Jeffry M, et al. Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades. Ann Saudi Med 2003; 23: 367-71.
9. Al-Ahdal M N, Kessie G, Rezeig M A, et al. Hepatitis C virus detection and genotyping in liver tissues and sera of Saudi patients using PCR and a line probe assay. Saudi Med J 1998; 19: 182-4.
10. Osoba A O. Hepatitis C virus Genotype in Saudi Arabia. Saudi Med J 2002; 23: 7-12.
11. Fakeeh M, Zaki A M. Hepatitis C. Prevalence and common genotype among ethic groups in Jeddah, Saudi Arabia. Am J of Trop Med Hyg 1999; 61: 889-92.
12. Al-Faleh F Z, Huraib S, Sbeih F, et al. Hepatitis C genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepatitis 1995; 2: 293-6.
13. Manns M P, McHutchison J G, Gordon S C, et al. PEG-interferon Alfa-2B in combination with ribavirn compared to interferon Alfa-2B in combination with Ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
14. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 647-53.
15. Heathcote E J, Shiffman M L, Cooksley W G, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
16. Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
17. Esmat G H, Abouzied A M, Abdel-Aziz F, et al. Results of a randomized clinical trial of genotype 4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin. Abstract 324 (poster). 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003, Boston, MA.
18. Shobokshi O, Emmanual K S, Shakni L, et al. Combination therapy of peginterferon alpha-2a (40 kd) (pegasys®) and ribavirin (Copegus®) significantly enhance sustained virological response in chronic hepatitis C genotype 4 patients with Saudi Arabia. Abstract 996 (poster). 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003, Boston, MA.
19. Hassan F, Asker H, Al-Khaldi J, et al. Pegylated interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis genotype 4. Abstract 982 (poster). 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003, Boston, MA.
20. Davis G L, Lau J Y, Urdea M S, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19: 1337-41.
21. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-102.
22. The METAVIR cooperative group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20: 15-20.
23. Al-Faleh F Z, Aljumah A, Rezeig M, et al. Treatment of chronic hepatitis C genotype 4 with interferon - ribavirin combination in Saudi Arabia: a multicenter study. J Viral Hepatitis 2000; 7: 287-91.
24. National Institutes of Health. NIH Consensus Development Conference Statement. Proceedings of the Management of Hepatitis C; 2002, June 10-12; Bethesda MD. Gastroenterology 2002; 123: 2082-99.
25. Diago M, Hadziyannis S J, Bodenheimer H Jr., et al. Optimized virological response in genotype 4 chronic hepatitis C patients treatment with peginterferon alfa-2a (40 KD) (pegasys) in combination with ribavirin (RBV). Hepatology 2002; 36: 364A.
26. Al-Faleh F Z, Sbeih F, Al-Karawi M, et al. Treatment of chronic hepatitis C genotype 4 with alpha-interferon in Saudi Arabia: a multicenter study. Hepato-Gastroenterology 1998; 45: 488-91.
27. Neumann A U, Lam N P, Dahari H, et al. Differences in viral dynamics between genotype 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
28. Pawlotsky J - M, Hezode C, Pellegrin B, et al. Early HCV genotype 4 replication kinetics during treatment with peginterferon alfa-2a (Pegasys)-ribavirin conmbination. A comparison with HCV genotype 1 and 3 kinetics. Hepatology 2002; 36: 291A.
29. Hadziyannis S, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40KD) (Pegasys®) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized double-blind, Multicentre study examining effect of duration of treatment and RBV dose. Abstract; European Association for the study of the Liver 37th meeting, April 18th-21st 2002, Madrid, Spain.
30. Lamb M W, Martin N E. Weight based versus fixed dosing of peginterferon (40KDa) alfa 2a. Ann Pharmcother 2000; 36: 933-5.